左旋甲状腺素治疗亚临床甲状腺功能减退症和心血管疾病的研究现状  

Research status of levothyroxine in the treatment of subclinical hypothyroidism and cardiovascular diseases

作　　者：魏晋红 路潇 胡鑫鑫 田利民[1,3] WEI Jin-hong;LU Xiao;HU Xin-xin;TIAN Li-min(The First Clinical Medical School,Lanzhou University,Lanzhou 730000,Gansu Province,China;The First Clinical Medical School,Gansu University of Traditional Chinese Medicine,Lanzhou 730000,Gansu Province,China;Department of Endocrinology,Gansu Provincial People’s Hospital,Lanzhou 730000,Gansu Province,China)

机构地区：[1]兰州大学第一临床医学院,甘肃兰州730000 [2]甘肃中医药大学第一临床医学院,甘肃兰州730000 [3]内分泌科甘肃省人民医院,甘肃兰州730000

出　　处：《中国临床药理学杂志》2022年第14期1696-1700,共5页The Chinese Journal of Clinical Pharmacology

基　　金：国家自然科学基金资助项目(82060152)。

摘　　要：亚临床甲状腺功能减退症(SCH)是轻度的甲状腺功能衰竭,促甲状腺激素和甲状腺激素浓度的细微变化都会对心血管系统产生不利影响。多项研究提示SCH与心血管疾病具有相关性。有研究表明亚临床甲状腺疾病的治疗可改善心血管危险因素,这意味着心血管疾病的可能获益。本文就SCH与心血管疾病风险的关联及其是否需要干预治疗等研究现状作一综述。Subclinical hypothyroidism(SCH) is a mild thyroid failure. Thyroid Stimulating Hormone(TSH) and subtle changes in the concentration of thyroid hormone will have an adverse effect on the cardiovascular system. A number of studies suggest that SCH is related to cardiovascular disease. Studies have shown that the treatment of subclinical thyroid disease can improve cardiovascular risk factors, which means that cardiovascular disease may benefit. This article reviews the research progress on the relationship between SCH and cardiovascular disease risk and whether intervention is needed.

关 键 词：亚临床甲状腺功能减退症 心血管疾病 相关性 病理生理机制 

分 类 号：R28[医药卫生—中药学]